TransitionCHF Systolic Dysfunction to Congestive Heart Failure Cohort Study

Exclusion Criteria

• •Symptomatic heart failure (NYHA\>I) at baseline visit
• •Any significant valvular disease (\> 2nd degree)
• •Severe pulmonary disease (e.g. FEV1/FVC \<0.7 and FEV1\<50%)
• •Severe renal disease (GFR \< 15 ml/min)
• •ejection fraction at baseline visit ≥ 50% by echocardiography or MRI
• •Life expectancy \< 1 year
• •Pericardial disease
• •Hypertrophic cardiomyopathy
• •Myocardial infarction within the last 3 months
• •Planned cardiac surgical intervention within 3 months after inclusion
• •Geographical reasons (e. g. patients living outside Germany or planning to move abroad)
• •Inability to give informed consent (e. g. mental disorders)
• •Therapy with loop diuretics (e.g. torasemide, furosemide, piretanide) within 4 weeks prior to inclusion/baseline visit